Efficacy and Safety of VB119 in Subjects With Membranous Nephropathy

Summary

This study is a Phase 1b/2a, open-label, sequential-cohort, dose escalation, and dose expansion study to evaluate the safety, tolerability, PK, and PD of VB119 in subjects with primary MN

Timeline

Start

2021-05-05

Primary completion

2023-11-21

Completion

2024-08-15

Outcome

Outcome not reported

Stopped: “Sponsor change”

Drugs

Indications